Biora Therapeutics, Inc. (BIOR)

Market Cap	26.23M
Revenue (ttm)	4,000
Net Income (ttm)	-124.12M
Shares Out	35.88M
EPS (ttm)	-7.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,367
Open	0.700
Previous Close	0.713
Day's Range	0.670 - 0.748
52-Week Range	0.585 - 6.700
Beta	1.09
Analysts	Strong Buy
Price Target	50.00 (+6,739.95%)
Earnings Date	May 13, 2024

About BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company's offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: BIOR

Financial Performance

In 2023, BIOR's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Analyst Forecast

According to one analyst, the rating for BIOR stock is "Strong Buy" and the 12-month stock price forecast is $50.0.

Price Target

$50.0

(6,739.95% upside)

Analyst Consensus: Strong Buy